The Series B preferred stock issued in the public offering is convertible into shares of the companys common stock at a conversion price of $2.00 per share. Each share of Series B preferred stock will be accompanied by (a) a Series 1 warrant, which expires on the earlier of (i) 60 days following the clearance by the FDA of a new lower-profile version of the companys Pantheris atherectomy system and (ii) the seventh anniversary of the warrants issuance, to purchase 500 shares of the companys common stock at an exercise price of $2.00 per share, and (b) a Series 2 warrant, which expires on the seventh anniversary of its issuance, to purchase 500 shares of the companys common stock at an exercise price of $2.00 per share.
da kann man froh sein, wenn diese erstmal gesperrt sind
, aber die Bs nicht... mal schauen ob deine 5 kommen
On February 14, 2018, the Company entered into a Series A Purchase Agreement with CRG, pursuant to which it agreed to convert $38,000,000 of the outstanding principal amount of its senior secured term loan (plus $3,800,000 in back-end fees and
Table of Contents
prepayment premium applicable thereto), totaling $41,800,000, into a newly authorized Series A preferred stock. The Series A preferred stock is initially convertible into 20,900,000 shares of common stock subject to certain limitations contained in the Series A Purchase Agreement. Under the terms of the Series A Purchase Agreement, the holders of Series A preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series A preferred stock or cash, at the Companys option. The shares of Series A preferred stock have no voting rights and rank senior to all other classes and series of the Companys equity in terms of repayment and certain other rights. The Series A preferred stock and any of the Companys common stock issued upon conversion of the Series A preferred stock are subject to a lockup agreement through February 14, 2019.